{"abstract": "Making a further move into the market for cardiovascular drugs, the biotechnology giant Amgen has formed an alliance with Cytokinetics, a smaller company developing an experimental drug to treat heart failure. Under the agreement, which is expected to be announced Wednesday, Amgen will pay Cytokinetics $75 million to gain an option on the drug, which is about to enter the second of three stages of clinical trials.", "web_url": "https://dealbook.nytimes.com/2007/01/03/amgen-acquires-option-for-a-heart-failure-drug/", "snippet": "", "lead_paragraph": "Making a further move into the market for cardiovascular drugs, the biotechnology giant Amgen has formed an alliance with Cytokinetics, a smaller company developing an experimental drug to treat heart failure. Under the agreement, which is expected to be announced Wednesday, Amgen will pay Cytokinetics $75 million to gain an option on the drug, which is about to enter the second of three stages of clinical trials.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Amgen Acquires Option for a Heart Failure Drug", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2007-01-03T12:23:08+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Dealbook", "person": [{"firstname": "Dealbook", "middlename": null, "lastname": "", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/018891e3-0147-51ba-aa33-08d031f6184b", "word_count": 74, "uri": "nyt://article/018891e3-0147-51ba-aa33-08d031f6184b"}